Please assess the completion status of the following clinical trial:

Trial Title: Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 2 diabetes~2. HbA1c ≥ 7.5%~3. Age ≥ 30~4. low HDL-C (\<40 mg/dl in men or \<50 mg/dl in women) and having 1 or more risk factors: 1) Body mass index (BMI) ≥ 25 kg/m2 (overweight); 2) LDL-C level ≥ 130 mg/dl; 3) TG level ≥150 mg/dl; 4) Systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥140/90 mmHg or taking antihypertensive medication; 5) Current smoker; 6) Family history of CHD.~Exclusion Criteria:~1. Contraindication to rosuvastatin~2. Pregnant or breast feeding women~3. Reproductive-age women who refuse contraception~4. Type 1 diabetes, gestational diabetes, or diabetes with secondary cause~5. Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT \> 3-fold the upper limit of normal)~6. Renal failure (Cr \> 2.0)~7. Cancer within 5 years (except squamous cell cancer, cervical cancer, thyroid cancer with appropriate treatment)~8. Not appropriate for lipid lowering treatment~9. Medications which affect glycemic control~10. Diseases which affect efficacy and safety of statin~11. Other clinical trial within 30 days

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin (Type: EXPERIMENTAL): Rosuvastatin will be started in type 2 DM and having 1 or more cardiovascular risk factors

Based on this trial design, predict the completion outcome and termination type (if applicable).